ORB-021
Phase 1Small molecule
ORB-021 is one of 11 small molecule programs targeting Advanced Solid Tumors Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Advanced Solid Tumors Cancer
#DrugCompanyPhaseTrials
1Abraxane
Bristol-Myers SquibbPreclinical
Gemzar
Johnson & JohnsonPreclinical
Camptosar
PfizerPreclinical
Eloxatin
TevaPreclinical
Erbitux
IImclone
Preclinical
Adrucil
EElorac, Inc.
Preclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
GT201
GGrit Biotechnology
Preclinical
IL-2
FFate Therapeutics
Preclinical
ORB-021
OOrionis Biosciences Inc
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ORB-021. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- OOrionis Biosciences Inc